Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies

Autor: Luigino Calzetta, Maria Gabriella Matera, Paola Rogliani, Beatrice Ludovica Ritondo, Alfredo Chetta
Přispěvatelé: Calzetta, L., Ritondo, B. L., Matera, M. G., Chetta, A., Rogliani, P.
Rok vydání: 2021
Předmět:
Zdroj: Expert Review of Respiratory Medicine. 16:357-365
ISSN: 1747-6356
1747-6348
Popis: Objectives: The recent publication of additional data retrieval for patients missing week 52 vital status in the original analyses of the ETHOS study provides the urgent need of updating previous network meta-analyses (NMA) to produce stronger evidence on mortality in patients receiving dual and triple FDCs according with the level of ICS dose. Methods: A NMA was performed to compare the effect of ICS/LABA/LAMA, ICS/LABA, and LABA/LAMA FDCs administered via the same inhaler device in COPD patients. The number need to treat (NNT) was also calculated. Results: When considering on-treatment all-cause of death (analyzed patients: 18,864), MD ICS/LABA/LAMA and MD ICS/LABA FDCs significantly reduced the risk of mortality vs. LABA/LAMA FDC (RR 0.59 95%CrI 0.35–0.97 and 0.61 95%CrI 0.38–0.99 respectively, P
Databáze: OpenAIRE